Invesco India Pharma and Healthcare Fund NFO opens today: Key details investors should know

Invesco Mutual Fund has launched the Invesco India Pharma and Healthcare Fund, an open-ended equity scheme investing in pharma, healthcare and allied sectors. The New Fund Offer (NFO) opened for subscription on August 18, 2026, and will close on September 1, 2026.

The fund will invest across pharmaceutical companies, hospitals, diagnostics, contract development and manufacturing organisations (CDMOs), contract research organisations (CROs), medical devices, healthcare services, insurance and other allied healthcare segments.

The scheme will be managed by Aditya Khemani, Head of Equity & Fund Manager at Invesco Mutual Fund, and will be benchmarked against the BSE Healthcare TRI. Invesco's official scheme information confirms the NFO dates, benchmark and fund manager.

Invesco sees structural opportunity in healthcare

“India's healthcare sector is undergoing a structural transformation. The country is not only witnessing rising healthcare consumption driven by favourable demographics and increasing affordability but is also strengthening its position as a global pharmaceutical and healthcare innovation hub. We see attractive opportunities across domestic pharma, hospitals, diagnostics, CDMOs and emerging healthcare segments that can potentially benefit from this multi-year growth cycle. Our investment approach will focus on identifying quality businesses with sustainable competitive advantages and strong growth visibility across the healthcare ecosystem.”

The fund house said India's healthcare sector is being supported by factors including rising healthcare expenditure, ageing demographics, increasing lifestyle diseases, wider health insurance coverage, infrastructure development and India's growing role in global pharmaceutical outsourcing.

Invesco India Pharma and Healthcare Fund: Key details

The scheme has a very high risk classification and is intended for investors seeking long-term capital appreciation through predominantly equity and equity-related investments in pharma, healthcare and allied companies.

The fund is not restricted to traditional pharmaceutical companies. Its mandate allows it to invest across different parts of the healthcare value chain, including hospitals, diagnostics, CDMOs, CROs, medical devices and healthcare services.

This gives the fund manager a wider investment universe within the healthcare theme. At the same time, investors should remember that this is a sector-focused equity fund, rather than a diversified equity scheme.

As a new fund, it also has no historical performance track record. The eventual performance will therefore need to be assessed against its BSE Healthcare TRI benchmark and the broader performance of the healthcare sector.

Invesco Asset Management (India) had ₹1,57,943 crore of average assets under management for the quarter ended March 2026, across mutual funds, PMS and offshore advisory, according to the company.